natgillin/translations-raw huggingface dataset:
Method according to anyone of claims 1 to 4, wherein the concentrator (C) transmits values indicating storage locations to the remote meter (RM) requesting transmission of said periodically measured and stored consumption related data stored in the storage locations indicated by said values. 
Metoda prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu sabirnik (C) prenosi vrijednosti koje označuju lokacije za pohranu do daljinskog brojača (RM) zahtijevajući prijenos navedenih periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju pohranjenih na lokacijama za pohranu označenim navedenim vrijednostima.
The compound for use according to claim 7, wherein said pain is selected from the group consisting of neuropathic pain, inflammatory pain, pain associated with cancer, pain associated with bone fracture, and pain associated with surgery. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 7, naznačen time što se navedenu bol bira iz skupine koju čine neuropatska bol, upalna bol, bol povezana s rakom, bol povezana s prijelomom kosti, te bol povezana s kirurškim zahvatom.
determine a displacement of the anchor by determining anchor acceleration values from the acquired acceleration data, measuring at least one further physical quantity associated with the anchoring by means of the one or more auxiliary sensors, 
HR P20181083 T1 ii. = određivanje pomaka sidra i to A. određivanjem vrijednosti ubrzanja sidra iz stečenih podataka o ubrzanju, B. mjerenjem najmanje jedne daljnje fizikalne veličine povezane sa sidrenjem pomoću jednog ili više pomoćnih senzora, 5
The receptacle (100; 200; 400; 500) for containing and dispensing solid medicinal pills according to claim 6, wherein said inlet is hingedly attached to an opening provided in a surface of said container (102), or wherein said inlet comprises an opening covered by a semi-flexible material having a resealably openable slit, or optionally wherein said inlet comprises a one-way valve. 
Spremnica (100; 200; 400; 500), namijenjena držanju i izdavanju čvrstih medicinskih pilula u skladu s patentnim zahtjevom 6, naznačena time što je navedeni ulaz uzglobljeno povezan s otvorom koji se nalazi na površini navedenog spremnika (102), ili gdje navedeni ulaz sadrži otvor pokriven polufleksibilnim materijalom koji ima pukotinu, koju se može tako otvoriti da je se može ponovno hermetički zatvoriti, ili gdje navedeni ulaz može sadržavati jedosmjerni ventil.
provided that when Z is sulfur and n is 1, then R1 and R3 are other than hydrogen. 
uz uvjet da kada je Z sumpor i n je 1, onda su R1iR3različiti od vodika.
The anti-IL-5 antibody for the use according to claim 5, wherein the mean plasma concentration of said antibody is 34.1 ± 12.1 µg/mL to 38.2 ± 9.1 µg/mL or wherein the AUC(0-inf) of said antibody is 1110 ± 372 µg×day/mL to 1196 ± 254 µg×day/mL. 
Protutijelo protiv IL-5, namijenjeno upotrebi u skladu s patentnim zahtjevom 5, naznačeno time što je srednja koncentracija u plazmi navedenog protutijela 34,1 + 12,1 ug/ml do 38,2 + 9,1 ug/ml i/ili što je AUC(o.<) Za navedeno protutijelo 1110 + 372 ugxdan/ml do 1196 + 254 ugxdan/ml.
Balance (Mettler Toledo or equivalent). Materials 
- - Vaga (Mettler Toledo ili njen ekvivalent).
is hydrogen, hydrocarbyl or substituted hydrocarbyl; 
R.2 je vodik, hidrokarbil ili supstituirani hidrokarbil;
After 2 hours stirring, the yellow solid was filtered and washed with cold EtOAc to an almost white solid. 
Nakon 2 sata miješanja žutu krutinu se filtrira, te ispere hladnim FtOAc do gotovo bijele krutine.
Embodiment 4. The pharmaceutical composition for use according to embodiment 1 wherein the crosslinked amine polymer has an equilibrium chloride binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer ("SGF") containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37 °C. 
Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-3, gdje je umreženi aminski polimer sa ravnotežnim kapacitetom vezanja klorida od najmanje 10 mmol/g u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaC1 1 63 mM FCI, pri pH 1,21 na 37%.
A power point as claimed in claim 6, characterised in that said light source (26, 28) is mounted on said card (10). 
Točka napajanja u skladu s patentnim zahtjevom 1, naznačena time što je navedeni izvor svjetla (26, 28) ugrađen na navedenu karticu (10).
The residues involved in the interaction of IL-18 with IL-18BP have been described through the use of computer modelling (Kim et al. 2000) and based on the interaction between the similar protein IL-1Bwith the IL-1R type I (Vigers et al. 1997). 
Aminokiselinski ostaci koji su uključeni u interakciji IL-18 s IL-18BP otkriveni su tehnikama računalnog modeliranja (Kim i sur., 2000), a baziraju se na primjeru interakcija između sličnih proteina IL-18 i IL-IR tipa I (Vigers i sur., 1997).
The garden water hose assembly (10) of claim 1 including indicia positioned on said material of the outer tube (12) wherein the indicia is readable while said assembly (10) is in either the contracted state, or in the expanded state, or in both the expanded state and the contracted state. 
Sklop cijevi za zalijevanje vrta (10) prema zahtjevu 1 naznačen time, da uključuje oznake postavljene na spomenuti materijal vanjske cijevi (12), pri čemu se oznake mogu čitati kada je navedeni sklop (10) ili u stegnutom stanju, ili u proširenom stanju, ili u stegnutom i proširenom stanju.
A therapeutic or prophylactic agent for irritable bowel syndrome with constipation, diabetic gastroparesis, or constipation, comprising the compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 25 as an active ingredient. 
Lijek prema patentnom zahtjevu 27, za uporabu kao terapeutsko ili profilaktičko sredstvo za sindrom iritabilnog crijeva sa konstipacijom, dijabetičku gastroparezu ili konstipaciju.
with a compound of formula (IV): 
(X) sa spojem sa formulom (IV): tBu
wherein "lower heterocycloalkyl" refers to a saturated or partly unsaturated non-aromatic ring moiety having 3 to 7 ring atoms bonded together to form a ring structure wherein one, two or three of the ring atoms is a heteroatom while the remaining ring atoms are carbon atoms; and 
pri čemu se "niži heterocikloalkil" odnosi na zasićeni ili djelomično nezasićeni ne-aromatski prstenski dio funkcionalne skupine, koji ima 3 do 7 atoma u prstenu vezanih zajedno za tvorbu prstenaste strukture gdje su jedan, dva ili tri atoma prstena heteroatomi dok preostali atomi u prstenu su atomi ugljika; te farmaceutski prihvatljivi esteri su metil esteri i etil esteri od kiselina formule I, koji se upotrebljavaju kao prolijekovi.
Gemzar® is currently administered by intravenous infusion at a dose of approximately 1000 to 1250 mg/m2 over 30 minutes, once weekly for up to 7 weeks followed by a week of rest from treatment. 
Gemzar" se trenutno primjenjuje intravenskom infuzijom, u dozi od približno 1000 do 1250 mg/m", u trajanju od 30 minuta, jednom tjedno, tijekom do 7 tjedana, uz tjedan dana odmora nakon liječenja.
Since the base unit is provided with means for sealingly connecting the container with the base unit to the base part, a pressure chamber is simply created by placing the container unit on the base part and placing the cover over the container unit and sealing it to base part. 
Budući da je osnovna jedinica opremljena sa sredstvom za tijesno spajanje spremnika s osnovnom jedinicom na osnovnom dijelu, tlačna komora se stvara jednostavno stavljanjem jedinice spremnika na osnovni dio i stavljanjem pokrova preko jedinice spremnika, te njegovim brtvljenjem na osnovni dio.
300 mg portions of the powder mixture were pressed with the heated tool, wherein pressure was maintained for at least 15 seconds by clamping the tabletting tool in a vice. 
Pomoću zagrijanog alata sprešano je uvijek 300 mg praškaste smjese, kod čega je pritisak prešanja održavan najmanje 15 s, pritezanjem alata za tabletiranje u škripcu.
Methods for the Preparation of Dihydrotetrabenazine Isomers 
Postupci pripreme izomera dihidrotetrabenazina
According to a further feature of this aspect of the invention there is provided a method for the prevention or treatment of those tumours which are sensitive to inhibition of one or more of the erbB family of receptor tyrosine kinases, such as a combination of EGFR and erbB2, that are involved in the signal transduction steps which lead to the proliferation and/or survival of tumour cells which comprises administering to said animal an effective amount of a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt thereof, as defined hereinbefore. 
Dodatna značajka ovog aspekta izuma je objava postupka za prevenciju ili liječenje tumora osjetljivih na inhibiciju jedne ili više receptorskih tirozin kinaza iz erbB porodice, poput kombinacije EGFR i erbB2, koje su uključene u korake prijenosa signala koji dovode do proliferacije i/ili preživljavanja tumorskih stanica, pri čemu se navedeni postupak sastoji od davanja spomenutoj životinji efektivne doze derivata kinazolina ili njegove farmaceutski prihvatljive soli, u skladu sa definicijom u gornjem tekstu.
The method of claim 7, wherein the myeloproliferative disorder is essential thrombocythemia (ET). The method of claim 7, wherein the myeloproliferative disorder is myeloid metaplasia with myelofibrosis (MMM). 
Spoj za upotrebu prema patentnom zahtjevu 18, naznačen time, što spomenuti mijeloproliferativni poremećaj predstavlja mijeloidna metaplazija sa mijelofibrozom (MMM); policitemija vera (PV) ili esencijalna trombocitemija (ET).
With reference to the above figures, the improved concealed hinge of this invention, globally indicated with 10 at figures 4 and 5, comprises a pair of half shells 12, 14, of metal or other suitable material that make up the support bodies suitable for being inserted and fixed into the cavities respectively obtained in the door and in the jamb. 
HR P20140060 T1 PATENTNI ZAHTJEVI Skrivena šarka (10), osobito namijenjena za panele namještaja ili vrata, načinjena od metala ili drugih pogodnih materijala, sadrži par poluploča (12-14), pogodnih za ubacivanje u prijemna mjesta vrata ili panela (48), te okvira
This fraction was discarded, since it contained only cell culture impurities. 
Ova frakcija je bila odbačena jer sadrži jedino nečistoće iz stanične kulture.
A GLA compound according to item 9, wherein x is 11, and the GLA compound has the following structure (IX): 
GLA spoj u skladu s patentnim zahtjevom 6, naznačen time što je x 11, a GLA spoj ima sljedeću strukturu (IX):
with the proviso that a carbon atom of the R1 heteroaryl is attached to the carbonyl; 
TO A o pooei uz uvjet da ugljikov atom iz R' heteroarila je vezan na karbonil;
Addition of sugars (e.g. 
Dodavanje šećera (na pr.
frequency transform means for transforming the low frequency component obtained by the core decoding means into a frequency domain; 
analizatora nisofrekventne vremenske ovojnice za analiziranje niskofrekventne komponente koju pretvarač frekvencije pretvara u frekventno područje kako bi se dobilo informacije o vremenskoj ovojnici;
the reaction of a compound of the formula (VI): 
(97) Broj objave europskog patenta:
The method of claim 14, wherein the dermatological composition is integrated in a medicated tape, topical dressing, or dermal patch. 
Uporaba prema jednom od zahtjeva 1 do 6, naznačena time da je navedeni spoj avermektina integriran u medicinsku traku, topikalni zavoj ili kožni flaster.
first transmission means (6,13,15,16,17) for transmitting the motion of said float (5) in a reciprocating rotary motion of said input shaft (19); 
prvi prijenosni sklop (6, 13, 15, 16, 17) za prijenos gibanja navedenog plovka (5), u naizmjeničnom rotacijskom kretanju navedenog ulaznog vratila (19);
A combination of a candle, a candle holder, and an outer cylinder as claimed in claim 1 wherein the body of the outer cylinder comprises a ledge extending transversely away from the outer cylinder. 
Aranžman sa svijećnjakom sukladno Zahtjevu 9 pri čemu tijelo (31) vanjskog cilindra (30) sadrži greben (36) koji se pruža transverzalno od vanjskog cilindra (30).
In some embodiments, the skin disease or disorder is dermatitis. In some embodiments, the dermatitis is allergic dermatitis, atopic dermatitis, dermatitis due to chemical exposure, or radiation-induced dermatitis. 
Farmaceutski pripravak za uporabu prema zahtjevu 33, naznačen time da je dermatitis alergijski dermatitis, atopijski dermatitis, dermatitis zbog kemijske izloženosti, ili dermatitis izazvan zračenjem.
A process according to claim 8 wherein the heating of the reaction mixture takes place until a temperature of around 95°C is reached. 
Postupak prema zahtjevu 8, naznačen time što se zagrijavanje reakcijske smjese provodi sve dok se ne postigne temperatura od oko .
The crude was re-crystallized from ethyl acetate and the product fractions were combined. 
Čvrste frakcije se rekristaliziraju iz etil acetata i završne frakcije međusobno spoje.
A hybridoma producing the antibody of any one of claims 1-9 or a hybridoma deposited under the accession no. 
Hibridom koji proizvodi antitijelo iz bilo kojeg od patentnih zahtjeva 1-9 ili hibridom koji je deponiran pod pristupnim br.
represents either represents a hydrogen atom or a C1-C3 alkyl group; 
R* predstavlja atom vodika ili C,-C; alkilnu skupinu;
The aqueous stoving binder of claim 2 wherein the phenolic compound A22 is a mono- or di-hydroxy aromatic compound. 
Vodeno vezivno sredstvo za peći prema zahtjevu 1, naznačeno time, da fenolski spoj A22 je mono- ili di-hidroksi-aromatski spoj.
A pharmaceutical composition according to any one of claims 1-12 further comprising an a4B7 inhibitor, a steroid, a MMP-9 antibody, a S1P1 agonist, a TNF biologic, or any combination thereof. 
Sastav koji sadrži spoj ili sastav prema bilo kojem od zahtjeva 1-17 i dodato antiinflamatorno sredstvo, gdje je spomenuto dodatno anti-inflamatorno sredstvo poželjno a4B7 inhibitor, steroid, MMP9 antitijelo, S1P1 agonist, TNF biološko sredstvo, ili bilo koja njihova kombinacija.
The compound according to any one of claims 1 to 4, wherein R1 is of the formula Rz*-NRa- wherein Ra is hydrogen, hydroxy, hydrocarbyloxy or hydrocarbyl, wherein hydrocarbyl has from 1 to 15 carbon atoms, is optionally interrupted by an -O- or -NH- linkage and is unsubstituted or is substituted by hydroxy, halo, amino or mono- or di-(C1-C4)alkylamino, alkanoyl having 4 in-chain atoms, trifluoromethyl, cyano, azo or nitro; 
je kisik, gdje R1 ima formulu R2-NRa-, gdje Ra je vodik, hidroksi, hidrokarbiloksi ili hidrokarbil, pro čemu hidrokarbil ima od 1 do 15 atoma ugljika, i po izboru je prekinut sa –O- ili –NH- lančanom poveznicom i nesupstituiran je ili supstituiran sljedećima: hidroksi, halo, amino ili mono- ili di-(C1-C4)alkilamino, alkanoil koji ima 4 atoma u prstenu, trifluorometil, cijano, azo ili nitro;
The process according to any one of claims 4 or 6, wherein the compound of formula (V) is obtained by reacting compound of formula (IV) with C1-4alkanol and an acid catalyst; and wherein the compound of formula (IV) is obtained by reacting compound of formula (III) with benzyl alcohol; in the presence of a coupling agent; or in the presence of an C1-4alkylchloroformate of the formula ClCOOR", wherein R'' is C1-4alkyl, such as methyl, ethyl, 1-propyl, 1-butyl, 2-butyl, and an organic base. 
Postupak prema bilo kojem zahtjevu 4 ili 6, naznačen time da je spoj formule (V) dobiven reakcijom spoja formule (IV) sa C1-4alkanolom i kiselim katalizatorom; te pri čemu je spoj formule (IV) dobiven reakcijom spoja formule (III) sa benzil alkoholom; u prisutnosti reakcijskog sredstva ili u prisutnosti C1-4alkilkloroformata formule ClCOOR", pri čemu R'' je C1-4alkil, kao metil, etil, 1-propil, 1-butil, 2-butil, i organske baze.
The charcoal weighed 0.375 g. 
Ugljen je težio 0.375 g.
A compound according to any of claims 1 to 10, wherein M is -NHC(O)R7, wherein R7 is C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, -NH-R10 or -NH-X1-R11, wherein R10 is C1-7 alkyl or C3-7 cycloalkyl, X1 is a bond or C1-7 alkyl, and R11 is a 5-6 membered heterocyclic ring optionally substituted by one or two C1-7 alkyl groups. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time, da je M -NHC(O)R;, pri čemu je R7 je Cr 7 alkil, C2; alkenil, Ca; cikloalkil, -NH-R,g ili X;-Ri 1, pri čemu je Ri9 C17 alkil ili C3.; cikloalkil, X; je veza ili CL; alkil, a R;, je petero do šesteročlani heterociklički prsten po izboru supstituiran s jednom ili dvije C,.; alkil skupine.
The dihydrogenphosphate salt is mentioned in the Prous online database (accession no. 2003: 3561) and the hydrochloride salt is disclosed in Drug Data Report 2003, 25(3), p.245-246 . 
Dihidrogenfosfatna sol spominje se u Prous online bazi podataka (br. pristupa. 2003:3561) a hidrokloridna sol je opisana u Drug Data Report 2003, 25(3), str.
Dosages of agents of the invention employed in practising the present invention will of course vary depending, e.g., on the particular condition to be treated, the effect desired and the mode of administration. 
Doziranje sredstva izuma upotrijebljenog u praktičnoj prvedbi predloženog izuma će se naravno mijenjati ovisno, npr. o posebnom stanju koje se želi liječiti, o željenom učinku i o načinu davanja.
This can be realised by providing a valve-like structure. 
To se može osigurati tako, da se stvori konstrukcija koja naliči na ventil.
the treatment of an immune system disease or disorder; or 
(ii) liječenje bolesti ili poremećaja imunološkog sustava; ili
filter, wash, and dry the solids. 
krutine filtrira, ispere, te osuši.
is a wet granulation formulation comprising the compound of Formula (I) and/or hydrate thereof, water, one or more effervescent agents, filler(s), binding agent(s) and disintegrant(s); 
(b) je formulacija vlažne granulacije koja sadrži spoj s Formulom (I) i/ili njegov hidrat, vodu, jedno ili više šumećih sredstava, punila, vezivno sredstvo(a) i sredstvo(a) za raspadanje;
Preferably said combination is used for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with a microbial infection. 
5. < Kombinacija prema zahtjevu 1 ili zahtjevu 2 naznačena time da je za upotrebu za ubijanje klinički latentnih mikroorganizama povezanih s mikrobnom infekcijom.
The seal-coat, and subsequently the enteric coat, are applied by spraying of an aqueous suspension of the coat ingredients in a Manesty XL coater using parameters for the coating process as recommended by the manufacturers of the coating polymers (again, any suitable coater could be used). 
Brtvena ovojnica, i nakon toga enterička ovojnica, se nanose sprejanjem vodene suspenzije sastojaka ovojnice u Manesty XL oblagaču upotrebom parametara za postupak oblaganja prema preporuci proizvođača polimera za oblaganje (ponovno, može se upotrijebiti bilo koji prikladni oblagač).
The Wave-generating apparatus (1), according to claim 1, wherein the profile (5) is flexible and may become deformed when the apparatus (1) is moving. 
Uređaj za generiranje valova (1), sukladno zahtjevu 1, pri čemu je profil (5) supstancijalno fleksibilan i može se deformirati kada se aparat (1) pomiče.
A pharmaceutical composition according to enbodiment 35, wherein said additional active agent is selected from IGF-1, IGF-2 or variants of IGF-1 or IGF-2, an anti-myostatin antibody, a myostatin propeptide, a myostatin decoy protein that binds ActRIIB but does not activate it, a beta 2 agonist, a Ghrelin agonist, a SARM, GH agonists/mimetics or follistatin. 
Farmaceutski sastav prema zahtjevu 20, naznačen time, da navedeno dodatno djelotvorno sredstvo je odabrano od sljedećih: IGF-1, IGF-2 ili varijante od IGF-1 ili IGF-2, protutijelo anti-miostatin, miostatin-propeptid, miostatin-decoy-protein koji veže ActRIIB, ali ga ne aktivira, beta 2-agonist, Ghrelin-agonist, SARM, GH-agonisti/mimetici i folistatin.
and R4, taken together with the adjacent nitrogen atom, form an azetidinyl, pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl ring, the piperidinyl ring being optionally substituted with one or two (C1-C2)alkyl group(s), and the piperazinyl ring being optionally substituted on the other N-atom with a (C1-C4)alkyl, benzyl, or phenylsulfonyl group; or a pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl ring fused with a benzene ring; 
R> i R", uzeti zajedno sa susjednim dušikovim atomom tvore azetidinilni, pirolidinilni, morfolinilni, piperidinilni ili piperazinilni prsten, a piperidinilni prsten može biti supstituiran s jednom ili dvjema (C;-C>)alkilnim skupinama, a piperazinilni prsten može biti supstituiran na drugom N-atomu sa (Cy-Cg)alkilnom, benzilnom ili fenilsulfonilnom skupinom; ili pirolidinilni, piperidinilni, morfolinilni ili piperazinilni prsten fuzioniran s benzenskim prstenom;
The host cell for use according to claim 10, wherein the host cell is a bacteria, optionally wherein the bacteria is selected from the group consisting of Roseburia species, lactic acid bacterium species, Lactococcus species, a Bifidobacterium species, a Lactobacillus species or a Propionibacterium species. A pharmaceutical composition and/or a nutritional supplement comprising a host cell expressing an exogenous Roseburia flagellin or variants, homologues, fragments or derivatives thereof and combinations thereof, and a pharmaceutically and/or nutritionally acceptable excipient, carrier or diluent. 
Farmaceutski pripravak i/ili prehrambeni (hranjivi) dodatak koji sadrži Roseburia flagelin, i/ili polinukleotidnu sekvencu koja kodira navedeni Roseburia flagelin, i/ili vektor koji sadrži navedenu polinukleotidnu sekvencu, i/ili stanicu domaćina, uključujući bakteriju, koja sadrži navedeni vektor, i/ili stanicu domaćina, uključujući bakteriju, koja sadrži navedenu polinukleotidnu sekvencu i farmaceutski i/ili prehrambeno prihvatljivo pomoćno sredstvo, nosač ili otapalo.
6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I or one of its derivatives having Notch signalling pathway inhibition properties, salts, solvates, tautomers, isomers thereof for use in the treatment and/or prevention of a cancer. 
Spoj za upotrebu u liječenju i/ili prevenciji Notch ovisnog raka naznačeno time da je spomenuti spoj koji ima inhibitorska svojstva Notch signalnog puta izabran među grupom koja se sastoji od:
A is selected from the group consisting of R5 is independently selected from the group consisting of alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, NRCRD, and (NRCRD)carbonyl; 
je neovisno odabran iz skupine koja se sastoji od alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, NRCRD i (NRCRD)karbonila;
The pyridone derivative, or a salt thereof, according to any of (1) to (7), wherein R4 in the formula (I) represents a halogen atom, a cyano group, a C1-C6 haloalkyl group, a C1-C6 alkoxy group, a hydroxymethyl group, a C1-C6 alkyl group, or a C2-C6 alkenyl group. 
Derivat piridona ili njegova sol prema patentnim zahtjevima 1 do 7, naznačen time da je R* u formuli (I) atom halogena, cijano grupa, C1-C6 haloalkil grupa, C1-C6 alkoksi grupa, hidrometil grupa, C1-C6 alkil grupa ili C2- C6 alkenil grupa.
adding diethylene glycol monoethyl ether to rifaximin, in a molar ratio ranging from 4:1 to about 500:1, at temperatures ranging from room temperature to 100° C. for a duration of time ranging from 5 minutes to 5 hours to provide a rifaximin solution; 
– otapanja rifaksimina u dietilen-glikol-monoetil-eteru (DEGME), u molarnom omjeru DEGME:rifaksimin u rasponu od 4:1 do 500:1, na temperaturama u rasponu od sobne temperature do 100 °C, u trajanju u rasponu od 5 minuta do 5 sati kako bi se dobilo otopinu rifaksimina;